Skip to content
DataLookout
Menu

NCT06295497

Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: 6 to 7
    • Site details revised
  2. Notable Enrollment target: 1000 to 3000v4 Show 6 more changesShow less
    • Primary completion date: Jun 30, 2027 to Sep 1, 2028
    • Primary endpoint revised
    • Eligibility criteria expanded, about 4 words
    • Study completion date: Dec 31, 2027 to Dec 1, 2028
    • Secondary endpoints: 5 to 6
    • Study title expanded, about 4 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2024 to Jul 18, 2024
    • Site details revised
    v3
  4. Notable Start date: Apr 1, 2024 to Dec 1, 2024
    • Site contact updated
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The prevalence of early-staged lung cancer detected by first-round LDCT thorax (T0) in a high-risk non-smoker population
Timeframe: 2 years

Secondary (7)

Sensitivity, specificity, positive predictive value and negative predictive value of AI-assisted programme in lung cancer detection
Diagnostic utility of plasma-based biomarker for detection and risk assessment of early-staged lung cancer
Rate of invasive workup and associated complications
Stage distribution of lung cancer detected by LDCT screening
Prevalence of lung cancer detected by second-round LDCT (T1) in patients with negative first-round LDCT
Show 2 moreShow less
Cost effectiveness of LDCT lung cancer screening using AI-assisted programme
Sensitivity, specificity, positive predictive value and negative predictive value of AI-assisted programme in lung nodule (≥5mm) detection and monitoring compared to radiologist assessment

Arms and interventions

Artificial intelligence-based programme (Lung-SIGHT)Other

Artificial intelligence (AI) algorithms have been demonstrated to function well and complement radiologists as second or concurrent readers in pulmonary nodule detection. AI Lung nodule detection and quantification solution are now widely used in the hospitals in the United Kingdom and at least eight other European countries. The sensitivity of nodule detection by radiologists increased from 72% to 80% with the aid of the AI programme. A clinical trial in Taiwan showed that using AI programme alone achieved an overall sensitivity of 95.6% in nodule detection, and superior performance in detecting nodule sized 4-5 mm comparing to radiologists. Overall, application of AI in CT analysis and lung nodule detection may significantly reduce the cost and workload of radiologist.

Devices: Lung-SIGHT

Sites

1 site in 1 country

  • Department of Clinical Oncology, Prince of Wales HospitalHong Kong, Hong Kong